Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.

NCT04755920 is registered in ClinicalTrials.gov with Leiden University Medical Center as lead sponsor.

NCT NCT04755920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04755920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Study of SGM-101, a Fluorochrome-labeled Anti-carcinoembryonic Antigen Monoclonal Antibody for the Intraoperative Detection of Colorectal Brain Metastases.
Lead sponsor
Leiden University Medical Center
Phase
Phase 2
Overall status
Unknown status
Start date
January 1, 2024
Completion date
February 28, 2026
Enrollment
10 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, brain diseases, brain metastases, brain neoplasms, brain tumor, colorectal neoplasms, gastrointestinal cancer, gastrointestinal disease, gastrointestinal neoplasms, intestinal disease, intestinal neoplasms, rectal neoplasms, rectum cancer